









Markets
/
Stocks
/
nasdaq-cprx
/

Catalyst Pharmaceuticals Inc

CPRX

19.780USD

-0.620-3.04%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

2.42BMarket Cap

11.60P/E TTM



Catalyst Pharmaceuticals Inc

19.780

-0.620-3.04%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

28 / 175

Overall Ranking

117 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

34.000

Target Price

+66.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 129.56% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 97.27.

Undervalued

The company’s latest PE is 11.42, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 109.05M shares, decreasing 4.12% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 8.74M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 9.35, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 146.56M, representing a year-over-year increase of 19.44%, while its net profit experienced a year-over-year increase of 27.73%.

Score

Industry at a Glance

Previous score

9.35

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.92

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.80, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 11.78, which is 20.55% below the recent high of 14.20 and -2.99% above the recent low of 12.13.

Score

Industry at a Glance

Previous score

1.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 28/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 9.25, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Catalyst Pharmaceuticals Inc is 33.00, with a high of 40.00 and a low of 31.00.

Score

Industry at a Glance

Previous score

9.25

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

34.000

Target Price

+66.67%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Catalyst Pharmaceuticals Inc

CPRX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.69, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 21.75 and the support level at 19.11, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.69

Change

-0.37

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.066

Neutral

RSI(14)

44.142

Neutral

STOCH(KDJ)(9,3,3)

37.635

Sell

ATR(14)

0.696

Low Volatility

CCI(14)

-48.667

Neutral

Williams %R

69.802

Sell

TRIX(12,20)

-0.126

Sell

StochRSI(14)

15.906

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

20.006

Sell

MA10

20.007

Sell

MA20

20.164

Sell

MA50

20.589

Sell

MA100

22.085

Sell

MA200

22.241

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 89.10%, representing a quarter-over-quarter decrease of 0.74%. The largest institutional shareholder is The Vanguard, holding a total of 8.74M shares, representing 7.14% of shares outstanding, with 1.31% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

16.42M

-2.43%

The Vanguard Group, Inc.

Star Investors

8.47M

+0.77%

State Street Global Advisors (US)

5.53M

-4.59%

McEnany (Patrick James)

4.28M

-4.46%

Renaissance Technologies LLC

Star Investors

2.96M

+9.25%

Deerfield Management Company, L.P.

3.42M

+9.23%

Geode Capital Management, L.L.C.

2.77M

+3.75%

Fundsmith LLP

2.15M

Morgan Stanley & Co. LLC

1.63M

+19.08%

Dimensional Fund Advisors, L.P.

2.19M

-27.40%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 5.62, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.80. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.